A Phase 2 study of M-CENK and N-803 with gemcitabine in ovarian cancer

Recruiting Phase 2 NCT06710288

Study Description

A Study Evaluating a Novel Cell Therapy and Immunotherapy Combination for Recurrent Ovarian Cancer

Study Details

Registry ID:: NCT06710288
Conditions:: Platinum-resistant Ovarian Cancer
Phase:: Phase 2
Target Enrollment:: 20 participants
Start Date:: November 6, 2024
Age Range:: 18–85 years
Gender:: Female
Healthy Volunteers:: No

Study Locations (2 sites)

Hoag
Newport Beach, CaliforniaUnited States, United States
Chan Soon-Shiong Institute for Medicine
El Segundo, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →